Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Session 9: Therapeutic antibodies: CancerFriday 14th November 2008. Moderator: Zdenka Jonak

Session 9: Therapeutic antibodies: CancerFriday 14th November 2008. Moderator: Zdenka Jonak Human Antibodies 17 (2008) 25–27 IOS Press Friday 14th November 2008. Moderator: Zdenka Jonak [09.00–09.30] Anticancer therapeutic antibody targeting cancer cell and tumor-associated activities Yan Wu ImClone Systems Incorporated, New York, USA Development of antibody-based cancer therapy has advanced substantially in research and clinical settings. The concept of antibody-directed therapeutic approaches was initially based on targeting a specific receptor or molecule that is expressed or functional in cancer cells. To achieve stronger antitumor effect, antibody combination and bispecific antibodies directed to cancer cells and other factors attributable to vascular or immune effector cells have been demonstrated to be effective in tumor treatment compared to single antibody based monotherapy. Conversely, an antibody directed to two or multiple molecules exerting functions in cancer cells, angiogenesis and other tumor-associated activities has been considered an attractive approach to achieving greater antitumor efficacy. Previously, we reported the antitumor activity of VEGFR-1 antibody through blocking the receptor-mediated functions in cancer and angiogenic cells. To date, the most difficult challenge to cancer intervention is the control of metastasis that accounts for most death of patients with cancer and the enhancement of antitumor immunity that is significantly weaken in most cancer patients. A number of growth http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Human Antibodies IOS Press

Session 9: Therapeutic antibodies: CancerFriday 14th November 2008. Moderator: Zdenka Jonak

Human Antibodies , Volume 17 (1) – Jan 1, 2008
Download PDF
3 pages

Loading next page...
 
/lp/ios-press/session-9-therapeutic-antibodies-cancerfriday-14th-november-2008-fZwYfYbKNK

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
IOS Press
Copyright
Copyright © 2008 by IOS Press, Inc
ISSN
1093-2607
eISSN
1875-869X
Publisher site
See Article on Publisher Site

Abstract

Human Antibodies 17 (2008) 25–27 IOS Press Friday 14th November 2008. Moderator: Zdenka Jonak [09.00–09.30] Anticancer therapeutic antibody targeting cancer cell and tumor-associated activities Yan Wu ImClone Systems Incorporated, New York, USA Development of antibody-based cancer therapy has advanced substantially in research and clinical settings. The concept of antibody-directed therapeutic approaches was initially based on targeting a specific receptor or molecule that is expressed or functional in cancer cells. To achieve stronger antitumor effect, antibody combination and bispecific antibodies directed to cancer cells and other factors attributable to vascular or immune effector cells have been demonstrated to be effective in tumor treatment compared to single antibody based monotherapy. Conversely, an antibody directed to two or multiple molecules exerting functions in cancer cells, angiogenesis and other tumor-associated activities has been considered an attractive approach to achieving greater antitumor efficacy. Previously, we reported the antitumor activity of VEGFR-1 antibody through blocking the receptor-mediated functions in cancer and angiogenic cells. To date, the most difficult challenge to cancer intervention is the control of metastasis that accounts for most death of patients with cancer and the enhancement of antitumor immunity that is significantly weaken in most cancer patients. A number of growth

Journal

Human Antibodies – IOS Press

Published: Jan 1, 2008

There are no references for this article.